Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 688: Acetylation of poly-ADP-ribose polymerase and Ku70 by histone deacetylase inhibitors promote abnormal binding to DNA double strand breaks and decrease repair efficiency in leukemia cells

Carine Robert, Ivana Gojo and Feyruz Rassool
Carine Robert
1University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivana Gojo
2Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feyruz Rassool
1University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-688 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Histone Deacetylase inhibitors (HDACi) affect gene expression through acetylation of histone and non-histone proteins which could alter their cellular activity. We have previously shown that HDACi trigger DNA damage responses in leukemia cells, and actual DNA Double Strand Breaks (DSBs) which are significantly increased and persist longer compared with normal cells. The mechanism by which this DNA damage occurs is still unknown. Non Homologous End Joining (NHEJ) is one of the main pathways for the repair of DSBs in mammalian cells. We have recently shown that NHEJ activity is abnormal in myeloid leukemias in that classical NHEJ that is Ku and DNA-PKcs dependent, is down regulated, and compensatory repair of DSBs occurs via alternative (Alt) NHEJ pathways involving Poly-ADP-Ribose Polymerase-1 (PARP-1) and DNA LigaseIIIα. Alt NHEJ is known to generate large deletions and translocations in cancers and leukemias. To determine whether HDACi may decrease the capacity of leukemic cells to repair DSBs by direct acetylation of NHEJ proteins, K562 and HL60 leukemia cell lines were treated with Trichostatin A (TSA, 300nM for 1 and 6 hours) followed by immunoprecipitation and western blot analysis for acetylated NHEJ proteins. TSA treatment of K562 and HL60 show differential acetylation of classical NHEJ protein Ku70 and Alt NHEJ protein PARP-1, compared with controls. To investigate whether TSA treatment alters the binding of Ku70 and PARP-1 to DSBs, we used a chromatin immunoprecipitation (CHIP) assay in K562 cell line stably transfected with DRNeo that can be induced to express a single DSB. Strikingly, CHIP analysis shows that PARP-1 is increased at the DSB after TSA treatment while Ku70 is not. To determine whether DSB repair activity is altered after HDACi treatment, we performed a plasmid based NHEJ repair assay in our leukemia cell lines after treatment with TSA. Both leukemia cell lines demonstrate a significant decrease in the capacity to repair DSBs following HDACi treatment. The same result can be obtained by the use of another HDACi entinostat. These data suggest that HDACi treatment leads to an increased presence of PARP-1 at DSBs, preventing subsequent critical repair steps in leukemia cells. Importantly, AML cells from patients treated with entinostat in vivo show significantly increased co-localization of PARP-1 and γH2A.x, a marker for DSBs, compared with pretreatment controls, confirming our in vitro data in leukemia cell lines. Overall, our results suggest that HDACi result in both a physical and functional alteration of proteins participating in both classical and Alt NHEJ, leading to a loss of binding of Ku70 and an abnormal persistence of PARP-1 at DSBs. Our data supports the idea that acetylated PARP-1 prevents repair of DSBs by Alt NHEJ, leading to a persistence of DSBs in leukemia cells treated with HDACi.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 688.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 688: Acetylation of poly-ADP-ribose polymerase and Ku70 by histone deacetylase inhibitors promote abnormal binding to DNA double strand breaks and decrease repair efficiency in leukemia cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 688: Acetylation of poly-ADP-ribose polymerase and Ku70 by histone deacetylase inhibitors promote abnormal binding to DNA double strand breaks and decrease repair efficiency in leukemia cells
Carine Robert, Ivana Gojo and Feyruz Rassool
Cancer Res April 15 2010 (70) (8 Supplement) 688; DOI: 10.1158/1538-7445.AM10-688

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 688: Acetylation of poly-ADP-ribose polymerase and Ku70 by histone deacetylase inhibitors promote abnormal binding to DNA double strand breaks and decrease repair efficiency in leukemia cells
Carine Robert, Ivana Gojo and Feyruz Rassool
Cancer Res April 15 2010 (70) (8 Supplement) 688; DOI: 10.1158/1538-7445.AM10-688
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - New Molecular Targets 2: Modulation of DNA Repair and Cell Death Pathways

  • Abstract 665: Targeting the pro-apoptotic protein BIM by dexamethasone combined with a MEK inhibitor PD184352 enhances the lethality in acute lymphoblastic leukemia
  • Abstract 682: Dual inhibition of BER by TRC102 and PARP inhibitor (ABT 888) synergistically enhances cytotoxicity of TMZ in human melanoma
  • Abstract 672: TumoraseTM: In vivo efficacy data for novel localized proteinase treatment applicable to solid tumors of varied tissue origins
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement